Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2013. The document serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility under the company's ShareReward Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of insider share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary Shares by several executives on January 10, 2013, at a price of 1381.19 pence per share. Transactions included both personal contributions and company matching contributions under the ShareReward Plan. No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to regulatory disclosure of share ownership changes.
Important Facts for Investors
- Share price for the reported transactions was 1381.19 pence per Ordinary Share.
- Transactions occurred on January 10, 2013, and were notified on January 11, 2013.
- Executives involved include Sir Andrew Witty, Mr S Dingemans, Mr S M Bicknell, Mr R G Connor, Mr D S Redfern, Ms C Thomas, Mr P C Thomson, Dr P J T Vallance, Ms E Walmsley, and Mrs V A Whyte.
- Most executives acquired 9 shares via personal contribution and 9 shares via company matching; Mr P C Thomson acquired 7 shares in each category.
- This filing does not contain financial results or strategic updates.